Ying Xia

Ying Xia

Auto-generated profile, based on publicly available information

Ying Xia

Department of Cell biology, School of Basic Medical Science, Southern Medical University, Guangzhou, PR China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2013 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
PDF file
YXYing Xia
Ying Xia
CKChristina M. L. Kelton
Christina M. L. Kelton
LXLiang Xue
Liang Xue
JGJeff J. Guo
Jeff J. Guo
BBBoyang Bian
Boyang Bian
PWPatricia R. Wigle
Patricia R. Wigle
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has raised safety concerns, especially the potential for severe asthma exacerbations (SAEs) resulting in hospitalizations or even death. Meanwhile, the use of inhaled corticosteroids (ICSs), a cornerstone in the treatment of mild-to-severe persistent asthma, has been associated with growth suppression in children. The purpose of this review was to identify and discuss the major published safety studies surrounding LABA, ICS, and combined LABA/ICS usage in children. By way of a critical search for influential published clinical trials, meta-analyses, and observational studies, six studies relevant to the safety of LABA monotherapy, seven studies relevant to ICS monotherapy, and four studies on the subject of LABA/ICS combination usage were identified and reviewed. Based on the reviewed literature, the controversy surrounding these anti-asthma medications was clearly exposed. On the one hand, there is some evidence that LABA monotherapy may be associated with SAEs and asthma-related death, while ICS monotherapy may be associated with a higher risk of growth suppression. On the other hand, the concurrent use of a LABA with an ICS has been associated with positive outcomes including symptom reduction and reduced rate and severity of exacerbations. Further clinical research is warranted and has been called for by the US Food and Drug Administration.

19 February 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
YXYing Xia
Ying Xia
WPWenbin Pan
Wenbin Pan
XXXiao Xiao
Xiao Xiao
XZXuejuan Zhou
Xuejuan Zhou
WGWenqing Gu
Wenqing Gu
MLMing Li
Ming Li